Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/57179
Title: Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.
Authors: 
Keywords: 
Issue Date: 8-Jan-2021
Citation: Pharmaceutics.2021;(13)1:
Abstract: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. An observational, longitudinal, prospective cohort study was conducted. The study population comprised 38 patients with IBD aged Genes were differentially expressed in non-responders and responders (32 before initiation of treatment and 44 after two weeks, Log2FC (Fold change) >0.6 or 0.6 or Expression of the FCGR1A, FCGR1B, and GBP1 genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD.
PMID: 33429950
URI: https://hdl.handle.net/20.500.12530/57179
Rights: openAccess
ISSN: 1999-4923
Appears in Collections:Fundaciones e Institutos de Investigación > FIB H. Infantil U. Niño Jesús > Artículos

Files in This Item:
File SizeFormat 
PMC7830359.pdf4.86 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons